Background {#Sec1}
==========

Aging is associated with ill health \[[@CR1]\], reflected in e.g. a greater disease burden \[[@CR2]\], and increasing prevalence of frailty \[[@CR3], [@CR4]\], chronic pain \[[@CR5]\], and concomitant morbidities \[[@CR6]\]. As a consequence, older people in the general population consume a disproportionally large part of prescription medications \[[@CR7]\]. This is problematic, as older and frail people have been found to be more sensitive to adverse effects \[[@CR8]\]. As a result, adverse effects are more common in older than in younger people \[[@CR9], [@CR10]\].

Although medical disorders should not be left untreated, some medications should be avoided or used restrictively in elderly populations. In 1991, Beers et al. \[[@CR11]\] published criteria for determining potentially inappropriate medication (PIM) use in nursing-home residents. These criteria have since then been extended to all older adults and are continuously revised by the American Geriatrics Society, with the latest revision published in 2015 \[[@CR12]\]. However, although several countries -- including Sweden \[[@CR13]\] -- have published guidelines for drug prescription, compliance is low when it comes to older people in the general population \[[@CR14]\]. It has been proposed that more than half of older people has at least one prescription of PIMs \[[@CR15]\], and some studies suggest that the risk of being prescribed PIMs are greater among women than among men \[[@CR15], [@CR16]\].

People with intellectual disability (ID) have a higher disease burden than the general population \[[@CR17]\]. Hence, drug prescription is expected to be higher among people with ID than in the general population. However, although some data suggest that frequency of prescribing corresponds to the frequency of chronic conditions \[[@CR18]\], others indicate high levels of excessive polypharmacy \[[@CR18]\] and off-label use, mainly for antipsychotics \[[@CR19]--[@CR21]\]. With respect to adverse effects, older people with ID may be more sensitive than the general population \[[@CR22]\]. Thus, it is important to describe prescription of PIMs among people with ID, in order to provide basis for actions to decrease adverse effects in this vulnerable population.

Methods {#Sec2}
=======

The aim of the present study was to investigate prescription of PIMs in a group of older people with ID in comparison with the same age group in the general population. Moreover, to describe potential differences based on sex, and to assess effects of sex, age, and living in special housing among people with ID. The study is register-based, using three Swedish national registers. The registers were used both to identify the study population and to collect information on exposure and outcome variables.

Setting {#Sec3}
-------

In Sweden, each person planning to stay in the country for at least one year is provided with his or her own unique personal identification number (PIN) at birth or immigration. In all registers described below, records are linked to a specific person using this PIN. Thus, record linking can be done to comprise a database with relevant register data.

The Total Population Register is maintained by the governmental administrative agency Statistics Sweden, with the aim to produce statistics about the Swedish population. The register contains information on life events including birth, marital status, and migration. Updates are transmitted daily from the Swedish Tax Agency.

Swedish people with ID or autism spectrum disorder (ASD) can apply to their municipalities for different measures of support, such as a personal assistant or day-time activities, to be able to live a full-filling life on the same terms as people in the rest of the population. These measures are regulated in the Swedish Act Concerning Support and Service for People with Certain Functional Impairments (aka the LSS) \[[@CR23]\]. There are ten forms of assistance specified in the act. One form is supported living in a group home or a service home, henceforth referred to as "special housing". In both types of special housing, each resident has his or her own apartment and access to common areas. Group homes are staffed around-the-clock, whereas in service homes, service staff is available at all hours, but not always on site. Special housing is available for adults as well as for children and young people. The other forms of support are advice and other personal support, personal assistance, companion service, contact person, relief service, short-term stays away from home, short-term care for schoolchildren over 12, and daily activities. All support and service provided according to the LSS act is documented in the LSS register, which is maintained by the Swedish National Board of Health and Welfare, a government agency under the Ministry of Health and Social Affairs. The register contains information on the individual, such as sex and date of birth, and on the services provided, such as type of service and providing municipality. It does not contain information on any diagnoses of ID or ASD.

The Swedish Prescribed Drugs Register was established in July 2005, and contains information on all dispensed prescriptions to the whole of Sweden's population. Also this register is maintained by the Swedish National Board of Health and Welfare. Each record contains information on the patient, such as age and sex, the drug, such as substance and dispensed amount, and the prescriber, such as profession and type of care facility. Drugs are defined using the Anatomical Therapeutic Chemical (ATC) classification system \[[@CR24]\]. As the name indicates, this system classifies drugs according to anatomical, therapeutic, and chemical group. E.g. all drugs classified in the main group "N" act on the nervous system. The system consists of five levels, where the fifth level identifies the chemical substance. The ATC classification system also includes Defined Daily Dose (DDD) for many drugs \[[@CR24]\]. The DDD is the average adult dose used for the main indication of the medicine.

Study cohorts {#Sec4}
-------------

The cohort of older people with ID (the ID cohort) was established using the LSS register. Through this register, all people aged at least 55 years and alive at December 31st 2012, and with at least one service registered during this year, were identified (*n* = 7936). The referent cohort (the gPop cohort) comprised people from the general population, one-to-one matched by sex and birth year by using the Total Population Register.

Outcomes {#Sec5}
--------

In 2010, the Swedish National Board of Health and Welfare published a report listing medications that may need extra attention among older people \[[@CR13]\]. Intermediate- or long-acting benzodiazepines (N05BA01, N05CD02, and N05CD03), medications with anticholinergic effects (anticholinergics; N05BB, G04, and R06AD), tramadol (N02AX), and propiomazine (N05CM) were listed under the heading "avoid unless special reason for prescription". All these were included as PIMs in the present study. The report further listed medications where a correct and current indication was particularly important. Of these, we included antipsychotics (N05A excluding lithium, N05AN), as it has been found commonly prescribed among people with ID \[[@CR19], [@CR25], [@CR26]\], and non-steroidal anti-inflammatory drugs (NSAIDs; M01A), as there are indications that pain may be under-treated among people with ID \[[@CR27]\]. Data on all dispensations of these medications during the period 2006--2012 were collected from the Prescribed Drug Register.

In the main analyses, we compared the ID cohort with the gPop cohort with respect to a) having at least one prescription of each medication during each year, b) number of years with prescription, and c) individual average DDD per medication during years with prescription. These analyses were performed for the whole cohorts, as well as stratified by sex. In secondary analyses, we investigated the effect of age, gender, and living in special housing on prescriptions of PIMs within the ID cohort.

Statistics {#Sec6}
----------

Analyses of dichotomous outcomes (e.g. having at least one prescription) were performed using generalized linear models (GLM), estimating relative risks (RRs) with 95% confidence intervals (CIs). When yearly observations were included in the model, calendar year was used to indicate repeated measures.

P-p-plots revealed that although the original values of individual average DDD were skewed, ln-transformed values were normally distributed. Thus, analyses were performed using Analysis of Variance (ANOVA) on ln-transformed values. As data regarding number of years with prescriptions were skewed both in their original form and after ln-transformation, comparisons were made using the Mann-Whitney U-test.

A two-tailed *p*-value of 0.05 was considered statistically significant. All statistical analyses were performed in IBM SPSS Statistics version 23.

Results {#Sec7}
=======

Of the 7936 individuals included in each cohort, 3609 (45%) were women and 4327 (55%) were men. The age at the start of the study period, i.e. in 2006, ranged between 49 and 90 years, and at the end of the study period between 55 and 96 years.

The percentage of people with prescription each year, as well as the number and percentage of people who were prescribed different medications at least once is described for the whole study period in Table [1](#Tab1){ref-type="table"}. The main results for the different medications/medication groups are presented below. Unless otherwise stated, the results found when comparing the ID cohort to the gPop cohort were consistent when stratifying on sex.Table 1Prescription of PIMs among people with ID and from the general populationYearly % with prescriptionNumber of years with prescription \[n (%)\]Median (range)1234567AllWomenMenAt least onegPop27--281822 (35)1093 (21)678 (13)501 (9)366 (7)352 (7)465 (9)*n* = 52772 (1--4)*n* = 24772 (1--4)*n* = 28002 (1--4)ID50--52997 (17)565 (10)359 (6)310 (5)268 (5)371 (6)2921 (50)*n* = 57917 (2--7)*n* = 26356 (2--7)*n* = 31567 (2--7)ID vs gPop\<0.001\<0.001\<0.001AnticholinergicsgPop4--6639 (51)218 (18)110 (9)82 (7)77 (6)57 (5)61 (5)*n* = 12441 (1--3)*n* = 4821 (1--2)*n* = 7622 (1--3)ID9--12545 (33)216 (13)180 (11)127 (8)106 (6)124 (7)372 (22)*n* = 16703 (1--6)*n* = 6553 (1--6)*n* = 10153 (1--6)ID vs gPop\<0.001\<0.001\<0.001BenzodiazepinesgPop2--3200 (47)58 (14)26 (6)18 (4)25 (6)33 (8)63 (15)*n* = 4232 (1--5)*n* = 2442 (1--5)*n* = 1792 (1--5)ID9--11548 (34)252 (16)132 (8)106 (7)75 (5)84 (5)412 (26)*n* = 16093 (1--7)*n* = 7222 (1--6)*n* = 8873 (1--7)ID vs gPop\<0.0010.006\<0.001NSAIDs^a^gPop16--191961 (45)969 (22)582 (13)361 (8)228 (5)164 (4)107 (2)*n* = 43722 (1--3)*n* = 20922 (1--3)*n* = 22802 (1--3)ID9--101422 (54)519 (20)259 (10)180 (7)87 (3)81 (3)80 (3)*n* = 26281 (1--3)*n* = 13311 (1--3)*n* = 12971 (1--2)ID vs gPop\<0.001\<0.001\<0.001PropiomazinegPop2--3369 (54)104 (15)58 (9)28 (4)38 (6)36 (5)46 (7)*n* = 6791 (1--3)*n* = 3611 (1--3)*n* = 3181 (1--3)ID7--9344 (29)159 (14)101 (9)93 (8)85 (7)87 (7)306 (26)*n* = 11753 (1--7)*n* = 5363 (1--7)*n* = 6393 (1--7)ID vs gPop\<0.001\<0.001\<0.001TramadolgPop4--5973 (65)245 (16)94 (6)50 (3)46 (3)41 (3)40 (3)*n* = 14891 (1--2)*n* = 7471 (1--2)*n* = 7421 (1--2)ID3--3585 (63)150 (16)62 (7)42 (5)38 (4)17 (2)33 (4)*n* = 9271 (1--2)*n* = 4881 (1--2)*n* = 4391 (1--2)ID vs gPop0.1870.2860.476Antipsychotics (excluding lithium)gPop1--188 (37)43 (18)21 (9)8 (3)16 (7)13 (6)46 (20)*n* = 2352 (1--6)*n* = 1162 (1--5)*n* = 1192 (1--6)ID34--34217 (7)140 (4)94 (3)93 (3)108 (3)194 (6)2270 (73)*n* = 31167 (6--7)*n* = 13377 (6--7)*n* = 17797 (6--7)ID vs gPop\<0.001\<0.001\<0.001Number of years with prescription of potentially inappropriate medications (PIMs) among 7936 people with intellectual disability (ID) and a sample from the general population (gPop) one-to-one matched on sex and age^a^Non-steroidal anti-inflammatory drugs

Potentially inappropriate medications {#Sec8}
-------------------------------------

There was an almost 90% increased risk for the ID cohort for yearly prescription of at least one PIM (Fig. [1](#Fig1){ref-type="fig"}). Half of the people in the ID cohort were prescribed at least one PIM during each year of the study period, compared to 9% in the gPop cohort (Table [1](#Tab1){ref-type="table"}). This resulted in a higher median number of years of prescription in the ID cohort. Among those with at least one prescription, the average DDD was higher in the ID cohort than in the gPop cohort (Fig. [2](#Fig2){ref-type="fig"}). Within the ID cohort, male gender, living in special housing, and increasing age was associated with being prescribed at least one PIM (Fig. [3](#Fig3){ref-type="fig"}).Fig. 1RRs for prescription of PIMs among people with ID compared with the general population. *Risk ratios with 95% confidence interval for prescription of potentially inappropriate medications (PIMs) for people with intellectual disability* vs *a one-to-one age and sex matched sample from the general population*. NSAIDs = Non-steroidal anti-inflammatory drugs; RRs are presented for the whole cohort (white; n=7936), men (black; n=4327), and women (gray; n=3609) Fig. 2Average DDD of PIMs for people with ID and the general population. *Geometric mean, maximum and minimum of individual average DDD (defined daily dose) for each potentially inappropriate medication (PIM) and cohort, displayed on a logarithmic scale*. NSAIDs = Non-steroidal anti-inflammatory drug; Black = gPop cohort, gray = ID cohort Fig. 3RRs for prescription of PIMs among people with ID. *Risk ratios with 95% confidence interval for prescription of potentially inappropriate medications (PIMs) within a group of people with intellectual disability.* NSAIDs = Non-steroidal anti-inflammatory drugs; White = special housing vs not special housing, black = men vs women, grey = age

Anticholinergics {#Sec9}
----------------

People in the ID cohort were more likely to be prescribed anticholinergic medications than those in the gPop cohort (Fig. [1](#Fig1){ref-type="fig"}), and the median number of years of prescription was higher in the ID cohort than in the gPop cohort (Table [1](#Tab1){ref-type="table"}). Among those with at least one prescription, the DDD was higher in the ID cohort than in the gPop cohort (Fig. [2](#Fig2){ref-type="fig"}). Within the ID cohort, male gender, living in special housing, and increasing age was associated with being prescribed anticholinergics at least once (Fig. [3](#Fig3){ref-type="fig"}).

Benzodiazepines {#Sec10}
---------------

People in the ID cohort were more likely to be prescribed benzodiazepines than those in the gPop cohort (Fig. [1](#Fig1){ref-type="fig"}), and the median number of years of prescription was higher in the ID cohort than in the gPop cohort (Table [1](#Tab1){ref-type="table"}). Among those with at least one prescription, the DDD was similar in the ID cohort and the gPop cohort (Fig. [2](#Fig2){ref-type="fig"}). Within the ID cohort, living in special housing, and decreasing age was associated with being prescribed benzodiazepines at least once (Fig. [3](#Fig3){ref-type="fig"}). No effect was found for gender.

NSAIDs {#Sec11}
------

People in the ID cohort were less likely to be prescribed NSAIDs than those in the gPop cohort (Fig. [1](#Fig1){ref-type="fig"}), and the median number of years of prescription was lower in the ID cohort than in the gPop cohort (Table [1](#Tab1){ref-type="table"}). Among those with at least one prescription, the DDD was lower in the ID cohort than in the gPop cohort (Fig. [2](#Fig2){ref-type="fig"}). Within the ID cohort, female gender, not living in special housing, and decreasing age was associated with being prescribed NSAIDs at least once (Fig. [3](#Fig3){ref-type="fig"}).

Propiomazine {#Sec12}
------------

People in the ID cohort were more likely to be prescribed propiomazine than those in the gPop cohort (Fig. [1](#Fig1){ref-type="fig"}), and the median number of years of prescription was higher in the ID cohort than in the gPop cohort (Table [1](#Tab1){ref-type="table"}). Among those with prescription of propiomazine, the DDD was higher in the ID cohort than in the gPop cohort (Fig. [2](#Fig2){ref-type="fig"}). Within the ID cohort, living in special housing was associated with being prescribed anticholinergics at least once (Fig. [3](#Fig3){ref-type="fig"}). No effects were found for gender or age.

Tramadol {#Sec13}
--------

People in the ID cohort were less likely to be prescribed tramadol than those in the gPop cohort (Fig. [1](#Fig1){ref-type="fig"}), but there was no difference between the ID and gPop cohorts with regards to number of years with prescription (Table [1](#Tab1){ref-type="table"}). Among those with at least one prescription, the DDD was higher in the ID cohort than in the gPop cohort (Fig. [2](#Fig2){ref-type="fig"}). Within the ID cohort, female gender, not living in special housing, and increasing age was associated with being prescribed anticholinergics at least once (Fig. [3](#Fig3){ref-type="fig"}).

Antipsychotics {#Sec14}
--------------

People in the ID cohort were more likely to be prescribed antipsychotics than those in the gPop cohort (Fig. [1](#Fig1){ref-type="fig"}). The results were consistent among men, but the number of women with prescription was too low to draw any conclusions. The median number of years of prescription was higher in the ID cohort than in the gPop cohort (Table [1](#Tab1){ref-type="table"}). Among those with at least one prescription, the DDD was higher in the ID cohort than in the gPop cohort (Fig. [2](#Fig2){ref-type="fig"}). Within the ID cohort, male gender, living in special housing, and increasing age was associated with being prescribed antipsychotics at least once (Fig. [3](#Fig3){ref-type="fig"}).

Discussion {#Sec15}
==========

People in the ID cohort were more likely than those in the gPop cohort to be prescribed all PIMs, except for those used in the management of pain. The same pattern, i.e. with increased risk of prescription of all PIMs except those used for pain management, was found when comparing those living in special housing to those living elsewhere within the ID cohort. Among people with ID, men were more likely than women to be prescribed anticholinergics and antipsychotics, but less likely to be prescribed medications for pain management. Increased risk of prescription was generally associated with prescription of higher doses and for longer periods of time. The exception was tramadol, where those with fewer prescriptions had higher doses.

Besides the size of the cohort of older people with ID, the present study has a major strength in that data on prescriptions were collected from a nationwide register covering all prescribed medicines dispensed at all pharmacies in Sweden. However, when interpreting the results, one must be aware that the register does not contain information on over-the-counter purchases, nor does it provide data on medications requisitioned for use in hospital wards. Moreover, data on medications administered in day care and outpatient care at hospitals are partially missing. Thus, the use of any such medications would be underestimated. If this underestimation differs between the ID and gPop cohorts, the risk estimates may also be compromised such that a greater underestimation of use in the ID cohort than in the gPop cohort would lead to an underestimation of the risk when comparing the ID cohort to the gPop cohort. The opposite result would follow if underestimation of use is more likely to occur in the gPop cohort than in the ID cohort.

We used inclusion in the LSS-register, i.e. having received support and service according to the LSS act, as a proxy for ID. There are two downsides with this. One is that the LSS register does not contain diagnoses but only registrations of which support and services have been provided. Thus, we have no information on type and severity of ID. Moreover, it is possible to be included in the LSS-register based on a diagnosis of ASD. Thus, the ID cohort may be "diluted" with people without ID but with ASD. In order to assess a possible impact of this, we defined subgroups within the ID cohort by using diagnoses from the Swedish National Patient Register: ASD-diagnosis only (*n* = 189), and ID-diagnosis only or in combination with ASD-diagnosis (*n* = 2147). The remaining 5600 people in the ID cohort had either not had a physician visit recorded during 2002--2012, or had other diagnoses than ASD or ID recorded for all visits. As the number of people with ID, alone or combination with ASD, is far greater than the number with ASD without ID, the impact of including also those with ASD should be minor.

In the present study, people with ID had higher risks of being prescribed PIMs than the general population. There may be several explanations for this. The most intuitive one is that the prescription rate corresponds to disorder prevalence. For example, anticholinergics are used in the treatment of gastrointestinal and respiratory disorders, which are common among people with ID \[[@CR17], [@CR28], [@CR29]\]. Moreover, people with ID are more likely to have co-morbidity than the general population \[[@CR17]\] and co-morbidity is correlated with use of PIMs \[[@CR30]\]. The same is true for mental disorders \[[@CR31], [@CR32]\]. However, in the case of benzodiazepines \[[@CR33]\] and propiomazine \[[@CR34]\], effective alternative treatments with less potential adverse effects are available. Thus, the large increased risk of prescription of these medications among older people with ID is a cause of concern, and more likely to reflect lack of awareness among prescribing health care professionals than a high disease burden among people with ID.

Besides various disorders, there are other factors associated with both ID and use of PIMs, and thereby possible links between these. These include low socioeconomic status \[[@CR35]--[@CR37]\] and unhealthy behavior, such as a sedentary lifestyle and improper nutrition \[[@CR38], [@CR39]\]. However, a more significant contributor is most likely the use of PIMs, such as antipsychotics, to treat challenging behavior among people with ID \[[@CR19]--[@CR21]\]. Also, prescription errors (i.e. prescription not in concordance with current standards) are frequent among older people with ID, with too high dosage and unnecessary drug therapy being the most common \[[@CR40]\].

The high prescription among people with ID may also be due to long-term use without proper evaluation of, or failure to recognize, adverse effects. For some of the PIMs investigated in the present study, i.e. antipsychotics, benzodiazepines, and anticholinergics, a common adverse effect is cognitive impairment \[[@CR12], [@CR13], [@CR41]\], which may be difficult to detect among people with ID. Others have adverse effects that are overlapping with disorders already common among people with ID, such as antipsychotics and constipation \[[@CR12], [@CR28]\]. Thus, unless particular attention is paid to potential adverse effects of PIMs in this group of people, they may go undetected, leading to even more deterioration of health.

Prescription of PIMs may be reduced by e.g. interventions targeted towards physicians \[[@CR42]\] or using computerized warning systems \[[@CR43]\]. These are methods not depending on the ability of the patient, and should thus be possible to use also among people with ID. However, medication reviews have been found feasible to perform among people with ID \[[@CR44], [@CR45]\]. Hence, higher prescription rate of PIMs, such as that found in the present study, should be avoidable. This might be achieved e.g. by educating care and health care professionals regarding the particular needs of people with ID, and the importance of continuous monitoring of adverse effects and re-evaluation of treatment regime.

A potential cause of concern is the lower prescription rate of medications used to treat pain, i.e. NSAIDs and tramadol, among people with ID compared with the general population. That we consider this possibly worrisome may be counterintuitive, as we have claimed these to be medications that should be avoided. If the lower prescription rate is an effect of less pain among people with ID, or that they are prescribed other -- better -- treatment regimes, it would be a positive result. However, this is most likely not the case \[[@CR46]--[@CR48]\]. As people with ID, and especially profound ID, are less able to conceptualize and communicate their symptoms \[[@CR49]\], it is more likely that the lower prescription rate is due to failure to recognize the pain rather than there being none \[[@CR27]\]. This is supported by other studies, where NSAIDs and opioids were found to be less prescribed among those with cognitive impairment \[[@CR50], [@CR51]\].

Within the ID cohort, increasing age was associated with prescription of at least one PIM, which is in agreement with previously published data \[[@CR52]--[@CR54]\]. In the general population, adverse effects associated with PIMs have been found to be more common among older people than in younger populations, and also to occur at lower doses \[[@CR41], [@CR55]\]. Notwithstanding the burden placed on the individual, the increased health care consumption due to use of PIMs \[[@CR56]--[@CR60]\] is also associated with increased health care costs for the society \[[@CR61]\]. Thus, to be aware of and monitor adverse effects is especially important in older patients with ID.

When comparing people with ID living in special housing to people with ID living elsewhere, the same pattern as when comparing people with ID to the general population emerged. This may not be surprising, as those living in special housing most likely have more health related problems. However, the increased risk of prescription of e.g. benzodiazepine could also be a result of a desire to keep residents more easily manageable.

In the present study, the risk of prescription of PIMs associated with ID was higher among men than among women. In the general population, women are more likely than men to be prescribed PIMs \[[@CR52], [@CR62]--[@CR64]\]. However, in the present study, they were less likely to be prescribed PIMs. Thus, the lower risk associated with ID among women compared to men is probably driven both by a higher prescription among women in the general population and a lower prescription among women among people with ID. Why opposite gender patterns are found in the general population and among people with ID needs to be further investigated.

Conclusions {#Sec16}
===========

PIMs are more common among people with ID than in the general population. They are also prescribed for longer periods and at higher doses. However, medications for pain management are less prescribed to people with ID, possibly since pain is under-recognized and under-treated in this population. There is a need for training and increased knowledge among care professionals regarding symptoms and signs of adverse effects. Also, for an awareness among health care professionals of the need of continuous evaluation of treatment in this vulnerable group.
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